Tweet
<img alt="" height="1" width="1" />
FDA panel backs approval of BioMarin's Morquio A Syndrome drug
Reuters
(Reuters) - A federal advisory panel has recommended approval of an experimental drug to treat a rare genetic disorder known as Morquio A Syndrome that causes skeletal malformation and a variety of related lung, eye, ear and heart problems. The panel ...
BioMarin Stock Trading Halted TodayMarketWatch
BioMarin Stock Trading Halted; FDA Reviews Vimizim ApplicationDrug Discovery & Development
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reached an intraday high of ...FinancialsTrend
Zacks.com -Zolmax -DailyFinance
all 17 news articles »
More...